HER2-targeted therapy influences CTC status in metastatic breast cancer / Thomas M. Deutsch, Sabine Riethdorf, Carlo Fremd, Manuel Feisst, Juliane Nees, Chiara Fischer, Andreas D. Hartkopf, Klaus Pantel, Andreas Trumpp, Florian Schütz, Andreas Schneeweiss, Markus Wallwiener
PURPOSE: As an independent, negative-prognostic biomarker for progression-free survival (PFS) and overall survival (OS), circulating tumor cells (CTCs) constitute a promising component for developing a liquid biopsy for patients with metastatic breast cancer (MBC). The effects of HER2-targeted therapy such as trastuzumab, pertuzumab, T-DM1, and lapatinib on CTC status and longitudinal enumeration were assessed in this trial. - METHODS: CTC status of 264 patients with MBC was analyzed prior to and after 4 weeks of a new line of palliative systemic therapy. CTCs were assessed using CellSearch®. Three groups were compared: patients with HER2-positive MBC receiving ongoing HER2-targeted therapy (n = 28), patients with de novo HER2-positive MBC and no HER2-targeted therapy in the last 12 months prior to enrollment and start of HER2-targeted therapy (n = 15), and patients with HER2-nonamplified disease and no HER2-targeted therapy (n = 212). - RESULTS: Positive CTC status (≥ 5 CTC/7.5 ml blood) at enrollment was observed in the 3 groups for 17.9, 46.7, and 46.2% (p = 0.02) of patients, respectively. At least one CTC/7.5 ml was seen in 28.6, 53.3, and 67.0% (p < 0.001) of these patients. Furthermore, 3.6, 40.0, and 3.3% (p < 0.001) of the patients had at least one HER2-positive CTC. After 4 weeks of therapy 7.1, 0.0, and 31.1% (p = 0.001) of patients had still a positive CTC status (≥ 5 CTC/7.5 ml blood). At least one CTC/7.5 ml was still observed in 25.0, 20.0, and 50.5% (p = 0.004) of the patients. Furthermore, 7.1, 0.0, and 1.9% (p = 0.187) had at least one HER2-positive CTC. After 3 months of therapy, 35.7, 20.0, and 28.3% (p = 0.536) showed disease progression. - CONCLUSIONS: HER2-targeted therapy seems to reduce the overall CTC count in patients with MBC. This should be taken into account when CTC status is used as an indicator for aggressive or indolent metastatic tumor disease..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 May 20 2020 |
|---|---|
| Erschienen: |
2020 May 20 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:182 |
|---|---|
| Enthalten in: |
Breast cancer research and treatment - 182(2020), 1, Seite 127-136 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deutsch, Thomas M., 1988- [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Gesehen am 20.10.2021 |
|---|
| Umfang: |
10 |
|---|
| doi: |
10.1007/s10549-020-05687-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1774601877 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1774601877 | ||
| 003 | DE-627 | ||
| 005 | 20240414193507.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211020s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10549-020-05687-2 |2 doi | |
| 035 | |a (DE-627)1774601877 | ||
| 035 | |a (DE-599)KXP1774601877 | ||
| 035 | |a (OCoLC)1295680510 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deutsch, Thomas M. |d 1988- |e verfasserin |0 (DE-588)1160897573 |0 (DE-627)1024291448 |0 (DE-576)506227960 |4 aut | |
| 245 | 1 | 0 | |a HER2-targeted therapy influences CTC status in metastatic breast cancer |c Thomas M. Deutsch, Sabine Riethdorf, Carlo Fremd, Manuel Feisst, Juliane Nees, Chiara Fischer, Andreas D. Hartkopf, Klaus Pantel, Andreas Trumpp, Florian Schütz, Andreas Schneeweiss, Markus Wallwiener |
| 264 | 1 | |c 2020 May 20 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.10.2021 | ||
| 520 | |a PURPOSE: As an independent, negative-prognostic biomarker for progression-free survival (PFS) and overall survival (OS), circulating tumor cells (CTCs) constitute a promising component for developing a liquid biopsy for patients with metastatic breast cancer (MBC). The effects of HER2-targeted therapy such as trastuzumab, pertuzumab, T-DM1, and lapatinib on CTC status and longitudinal enumeration were assessed in this trial. - METHODS: CTC status of 264 patients with MBC was analyzed prior to and after 4 weeks of a new line of palliative systemic therapy. CTCs were assessed using CellSearch®. Three groups were compared: patients with HER2-positive MBC receiving ongoing HER2-targeted therapy (n = 28), patients with de novo HER2-positive MBC and no HER2-targeted therapy in the last 12 months prior to enrollment and start of HER2-targeted therapy (n = 15), and patients with HER2-nonamplified disease and no HER2-targeted therapy (n = 212). - RESULTS: Positive CTC status (≥ 5 CTC/7.5 ml blood) at enrollment was observed in the 3 groups for 17.9, 46.7, and 46.2% (p = 0.02) of patients, respectively. At least one CTC/7.5 ml was seen in 28.6, 53.3, and 67.0% (p < 0.001) of these patients. Furthermore, 3.6, 40.0, and 3.3% (p < 0.001) of the patients had at least one HER2-positive CTC. After 4 weeks of therapy 7.1, 0.0, and 31.1% (p = 0.001) of patients had still a positive CTC status (≥ 5 CTC/7.5 ml blood). At least one CTC/7.5 ml was still observed in 25.0, 20.0, and 50.5% (p = 0.004) of the patients. Furthermore, 7.1, 0.0, and 1.9% (p = 0.187) had at least one HER2-positive CTC. After 3 months of therapy, 35.7, 20.0, and 28.3% (p = 0.536) showed disease progression. - CONCLUSIONS: HER2-targeted therapy seems to reduce the overall CTC count in patients with MBC. This should be taken into account when CTC status is used as an indicator for aggressive or indolent metastatic tumor disease. | ||
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Antibodies, Monoclonal, Humanized | |
| 650 | 4 | |a Antineoplastic Combined Chemotherapy Protocols | |
| 650 | 4 | |a Breast Neoplasms | |
| 650 | 4 | |a Circulating tumor cells (CTC) | |
| 650 | 4 | |a Disease Progression | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Follow-Up Studies | |
| 650 | 4 | |a HER2-targeted therapy | |
| 650 | 4 | |a Human epidermal growth factor receptor 2 (HER2) | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Lapatinib | |
| 650 | 4 | |a Metastatic breast cancer (MBC) | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Neoplastic Cells, Circulating | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Receptor, ErbB-2 | |
| 650 | 4 | |a Retrospective Studies | |
| 650 | 4 | |a Survival Rate | |
| 650 | 4 | |a Trastuzumab | |
| 700 | 1 | |a Riethdorf, Sabine |e verfasserin |0 (DE-588)1027790399 |0 (DE-627)729735001 |0 (DE-576)375318909 |4 aut | |
| 700 | 1 | |a Fremd, Carlo |d 1986- |e verfasserin |0 (DE-588)1064853579 |0 (DE-627)815228813 |0 (DE-576)424196212 |4 aut | |
| 700 | 1 | |a Feißt, Manuel |d 1989- |e verfasserin |0 (DE-588)1158520948 |0 (DE-627)1020533544 |0 (DE-576)504012312 |4 aut | |
| 700 | 1 | |a Nees, Juliane |d 1989- |e verfasserin |0 (DE-588)108222295X |0 (DE-627)84721270X |0 (DE-576)455206988 |4 aut | |
| 700 | 1 | |a Fischer, Chiara |d 1993- |e verfasserin |0 (DE-588)1270726439 |0 (DE-627)1819460142 |4 aut | |
| 700 | 1 | |a Hartkopf, Andreas |d 1979- |e verfasserin |0 (DE-588)139124101 |0 (DE-627)703216279 |0 (DE-576)309901596 |4 aut | |
| 700 | 1 | |a Pantel, Klaus |d 1960- |e verfasserin |0 (DE-588)1027683606 |0 (DE-627)729554929 |0 (DE-576)373549997 |4 aut | |
| 700 | 1 | |a Trumpp, Andreas |d 1964- |e verfasserin |0 (DE-588)1081774134 |0 (DE-627)846650266 |0 (DE-576)454773552 |4 aut | |
| 700 | 1 | |a Schütz, Florian |d 1972- |e verfasserin |0 (DE-588)12303387X |0 (DE-627)082307229 |0 (DE-576)293528810 |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e verfasserin |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Wallwiener, Markus |d 1980- |e verfasserin |0 (DE-588)134044827 |0 (DE-627)692043934 |0 (DE-576)27468327X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer research and treatment |d Dordrecht [u.a.] : Springer Science + Business Media B.V., 1981 |g 182(2020), 1, Seite 127-136 |h Online-Ressource |w (DE-627)320433722 |w (DE-600)2004077-5 |w (DE-576)104194162 |x 1573-7217 |7 nnns |
| 773 | 1 | 8 | |g volume:182 |g year:2020 |g number:1 |g pages:127-136 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10549-020-05687-2 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a ISIL_DE-16 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_711 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2472 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4328 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 951 | |a AR | ||
| 952 | |d 182 |j 2020 |e 1 |h 127-136 |g 10 | ||
| 980 | |2 2011 |1 01 |x DE-16 |b 3991737736 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 20-10-21 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 3991714353 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 20-10-21 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 4001034573 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 10-11-21 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://doi.org/10.1007/s10549-020-05687-2 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2020 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_ | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_10 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1580313981 |a Deutsch, Thomas M. | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416740961 |a Universitäts-Frauenklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_1 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1543892353 |a Fremd, Carlo | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)169133667X |a Zentrum für Innere Medizin (Krehl Klinik) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_3 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s p |0 (DE-627)1574012819 |a Feißt, Manuel | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s k |0 (DE-627)1416741593 |a Institut für Medizinische Biometrie und Informatik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |a pos_4 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s p |0 (DE-627)1529365163 |a Nees, Juliane | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s k |0 (DE-627)1416740961 |a Universitäts-Frauenklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |a pos_5 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s p |0 (DE-627)182444110X |a Fischer, Chiara | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |a pos_6 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s p |0 (DE-627)1586540564 |a Trumpp, Andreas | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s k |0 (DE-627)1416535500 |a Fakultät für Biowissenschaften | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |a pos_9 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s p |0 (DE-627)1450003788 |a Schütz, Florian | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s s |a pos_10 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s p |0 (DE-627)1436041317 |a Schneeweiss, Andreas | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s k |0 (DE-627)1416740961 |a Universitäts-Frauenklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s s |a pos_11 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 12 |s p |0 (DE-627)1481111221 |a Wallwiener, Markus | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 12 |s k |0 (DE-627)1416740961 |a Universitäts-Frauenklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 12 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 12 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 12 |s s |a pos_12 | ||